Patients in Gilead's Phase III MYR301 Hepatitis B trial of Hepcludex who did show any initial response to treatment are now responding.

Gilead Sciences is on the brink of getting full approval for the first drug for hepatitis D virus (HDV) in the EU, after getting a positive opinion from the EMA’s human medicines committee.

Chronic hepatitis delta virus (HDV) infection patients are currently bereft of approved treatment options in the U.S., but that could soon change thanks in part to a positive readout from one of Gilead Sciences’ recently acquired liver disease prospects.

Gilead Sciences is planning to file for approval of Hepcludex, its antiviral therapy for rare hepatitis D virus (HDV) in the US later this year, after the drug’s safety and efficacy was shown in late-stage clinical trials.